Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma

Simone Ferrero, Luigia Monitillo, Barbara Mantoan, Daniela Barbero, Elisa Genuardi, Sara Barbiero, Elisa Bernocco, Daniele Caracciolo, Marco Ruella, Daniela Drandi, Manuela Zanni, Federica Renna, Chiara Lobetti Bodoni, Angela Gueli, Roberto Passera, Pellegrino Musto, Mario Boccadoro, Corrado Tarella, Marco Ladetto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Pre-emptive rituximab (pRTX) might represent an effective approach for patients with follicular (FL) and mantle cell lymphoma (MCL) experiencing molecular relapse (M-rel). However, available experience is still limited. We retrospectively collected FL and MCL cases that underwent pRTX with four weekly rituximab infusions (375 mg/m2) due to molecular persistence or M-rel. M-rel was assessed using nested polymerase chain reaction (PCR) and real-time quantitative PCR using the Bcl-1/IGH, Bcl-2/IGH or the immunoglobulin heavy chain rearrangement. Twenty-three occurrences of M-rel or persistence were treated in 18 patients (nine MCL and nine FL). The pRTX reinduced molecular remission (MR) in 17/23 cases (7/9 FL and 10/14 MCL). The median time to MR reinduction was 4.5 months (range 3-12), and the median duration of the first MR reinduction was 34 months (range 12-72). In five MCL cases, pRTX was used to treat subsequent M-rels, with success in four cases. No clinical relapses were seen within 2 years of successful reinduction of MR. Progression-free survival after pRTX was 64 % at a median follow-up of 6 years. pRTX was feasible and safe and effectively reinduced MR in FL and MCL patients (74 %). Prospective trials are needed to verify the clinical benefit of similar approaches.

Original languageEnglish
Pages (from-to)1503-1511
Number of pages9
JournalAnnals of Hematology
Volume92
Issue number11
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Mantle-Cell Lymphoma
Recurrence
Therapeutics
Immunoglobulin Heavy Chains
Rituximab
Disease-Free Survival
Real-Time Polymerase Chain Reaction
Polymerase Chain Reaction

Keywords

  • Lymphoma
  • Minimal residual disease
  • PCR
  • Pre-emptive rituximab
  • Tailored treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Ferrero, S., Monitillo, L., Mantoan, B., Barbero, D., Genuardi, E., Barbiero, S., ... Ladetto, M. (2013). Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. Annals of Hematology, 92(11), 1503-1511. https://doi.org/10.1007/s00277-013-1797-y

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. / Ferrero, Simone; Monitillo, Luigia; Mantoan, Barbara; Barbero, Daniela; Genuardi, Elisa; Barbiero, Sara; Bernocco, Elisa; Caracciolo, Daniele; Ruella, Marco; Drandi, Daniela; Zanni, Manuela; Renna, Federica; Lobetti Bodoni, Chiara; Gueli, Angela; Passera, Roberto; Musto, Pellegrino; Boccadoro, Mario; Tarella, Corrado; Ladetto, Marco.

In: Annals of Hematology, Vol. 92, No. 11, 11.2013, p. 1503-1511.

Research output: Contribution to journalArticle

Ferrero, S, Monitillo, L, Mantoan, B, Barbero, D, Genuardi, E, Barbiero, S, Bernocco, E, Caracciolo, D, Ruella, M, Drandi, D, Zanni, M, Renna, F, Lobetti Bodoni, C, Gueli, A, Passera, R, Musto, P, Boccadoro, M, Tarella, C & Ladetto, M 2013, 'Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma', Annals of Hematology, vol. 92, no. 11, pp. 1503-1511. https://doi.org/10.1007/s00277-013-1797-y
Ferrero S, Monitillo L, Mantoan B, Barbero D, Genuardi E, Barbiero S et al. Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. Annals of Hematology. 2013 Nov;92(11):1503-1511. https://doi.org/10.1007/s00277-013-1797-y
Ferrero, Simone ; Monitillo, Luigia ; Mantoan, Barbara ; Barbero, Daniela ; Genuardi, Elisa ; Barbiero, Sara ; Bernocco, Elisa ; Caracciolo, Daniele ; Ruella, Marco ; Drandi, Daniela ; Zanni, Manuela ; Renna, Federica ; Lobetti Bodoni, Chiara ; Gueli, Angela ; Passera, Roberto ; Musto, Pellegrino ; Boccadoro, Mario ; Tarella, Corrado ; Ladetto, Marco. / Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. In: Annals of Hematology. 2013 ; Vol. 92, No. 11. pp. 1503-1511.
@article{d0937580fdc843d1833c240c142d8522,
title = "Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma",
abstract = "Pre-emptive rituximab (pRTX) might represent an effective approach for patients with follicular (FL) and mantle cell lymphoma (MCL) experiencing molecular relapse (M-rel). However, available experience is still limited. We retrospectively collected FL and MCL cases that underwent pRTX with four weekly rituximab infusions (375 mg/m2) due to molecular persistence or M-rel. M-rel was assessed using nested polymerase chain reaction (PCR) and real-time quantitative PCR using the Bcl-1/IGH, Bcl-2/IGH or the immunoglobulin heavy chain rearrangement. Twenty-three occurrences of M-rel or persistence were treated in 18 patients (nine MCL and nine FL). The pRTX reinduced molecular remission (MR) in 17/23 cases (7/9 FL and 10/14 MCL). The median time to MR reinduction was 4.5 months (range 3-12), and the median duration of the first MR reinduction was 34 months (range 12-72). In five MCL cases, pRTX was used to treat subsequent M-rels, with success in four cases. No clinical relapses were seen within 2 years of successful reinduction of MR. Progression-free survival after pRTX was 64 {\%} at a median follow-up of 6 years. pRTX was feasible and safe and effectively reinduced MR in FL and MCL patients (74 {\%}). Prospective trials are needed to verify the clinical benefit of similar approaches.",
keywords = "Lymphoma, Minimal residual disease, PCR, Pre-emptive rituximab, Tailored treatment",
author = "Simone Ferrero and Luigia Monitillo and Barbara Mantoan and Daniela Barbero and Elisa Genuardi and Sara Barbiero and Elisa Bernocco and Daniele Caracciolo and Marco Ruella and Daniela Drandi and Manuela Zanni and Federica Renna and {Lobetti Bodoni}, Chiara and Angela Gueli and Roberto Passera and Pellegrino Musto and Mario Boccadoro and Corrado Tarella and Marco Ladetto",
year = "2013",
month = "11",
doi = "10.1007/s00277-013-1797-y",
language = "English",
volume = "92",
pages = "1503--1511",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma

AU - Ferrero, Simone

AU - Monitillo, Luigia

AU - Mantoan, Barbara

AU - Barbero, Daniela

AU - Genuardi, Elisa

AU - Barbiero, Sara

AU - Bernocco, Elisa

AU - Caracciolo, Daniele

AU - Ruella, Marco

AU - Drandi, Daniela

AU - Zanni, Manuela

AU - Renna, Federica

AU - Lobetti Bodoni, Chiara

AU - Gueli, Angela

AU - Passera, Roberto

AU - Musto, Pellegrino

AU - Boccadoro, Mario

AU - Tarella, Corrado

AU - Ladetto, Marco

PY - 2013/11

Y1 - 2013/11

N2 - Pre-emptive rituximab (pRTX) might represent an effective approach for patients with follicular (FL) and mantle cell lymphoma (MCL) experiencing molecular relapse (M-rel). However, available experience is still limited. We retrospectively collected FL and MCL cases that underwent pRTX with four weekly rituximab infusions (375 mg/m2) due to molecular persistence or M-rel. M-rel was assessed using nested polymerase chain reaction (PCR) and real-time quantitative PCR using the Bcl-1/IGH, Bcl-2/IGH or the immunoglobulin heavy chain rearrangement. Twenty-three occurrences of M-rel or persistence were treated in 18 patients (nine MCL and nine FL). The pRTX reinduced molecular remission (MR) in 17/23 cases (7/9 FL and 10/14 MCL). The median time to MR reinduction was 4.5 months (range 3-12), and the median duration of the first MR reinduction was 34 months (range 12-72). In five MCL cases, pRTX was used to treat subsequent M-rels, with success in four cases. No clinical relapses were seen within 2 years of successful reinduction of MR. Progression-free survival after pRTX was 64 % at a median follow-up of 6 years. pRTX was feasible and safe and effectively reinduced MR in FL and MCL patients (74 %). Prospective trials are needed to verify the clinical benefit of similar approaches.

AB - Pre-emptive rituximab (pRTX) might represent an effective approach for patients with follicular (FL) and mantle cell lymphoma (MCL) experiencing molecular relapse (M-rel). However, available experience is still limited. We retrospectively collected FL and MCL cases that underwent pRTX with four weekly rituximab infusions (375 mg/m2) due to molecular persistence or M-rel. M-rel was assessed using nested polymerase chain reaction (PCR) and real-time quantitative PCR using the Bcl-1/IGH, Bcl-2/IGH or the immunoglobulin heavy chain rearrangement. Twenty-three occurrences of M-rel or persistence were treated in 18 patients (nine MCL and nine FL). The pRTX reinduced molecular remission (MR) in 17/23 cases (7/9 FL and 10/14 MCL). The median time to MR reinduction was 4.5 months (range 3-12), and the median duration of the first MR reinduction was 34 months (range 12-72). In five MCL cases, pRTX was used to treat subsequent M-rels, with success in four cases. No clinical relapses were seen within 2 years of successful reinduction of MR. Progression-free survival after pRTX was 64 % at a median follow-up of 6 years. pRTX was feasible and safe and effectively reinduced MR in FL and MCL patients (74 %). Prospective trials are needed to verify the clinical benefit of similar approaches.

KW - Lymphoma

KW - Minimal residual disease

KW - PCR

KW - Pre-emptive rituximab

KW - Tailored treatment

UR - http://www.scopus.com/inward/record.url?scp=84885584065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885584065&partnerID=8YFLogxK

U2 - 10.1007/s00277-013-1797-y

DO - 10.1007/s00277-013-1797-y

M3 - Article

VL - 92

SP - 1503

EP - 1511

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 11

ER -